Crosslinked Hyaluronic Acid Composition for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Uncrosslinked hyaluronic acid has a short in vivo half-life and significant decomposition, while high crosslinking agent ratios cause side effects, and lowering ratios compromises durability and physical properties.
Innovation Solution
A drug delivery composition using two crosslinked hyaluronic acids with different swelling ratios, controlled through crosslinking and purification, to manage decomposition period and release rate, ensuring effective and safe drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If a high ratio of crosslinking agent is used to form crosslinked hyaluronic acid gel, then the durability and physical properties are improved, but the probability of side effects increases
Solution Approach 1:
The patent applies parameter changes by using a low ratio of crosslinking agent (0.01-5 mol%) compared to conventional methods, while compensating through optimized crosslinking conditions and purification processes to achieve the desired gel strength and durability with reduced side effects
Solution Approach 2:
The patent extracts and removes excess crosslinking agent through a purification process involving dialysis or gel filtration chromatography, thereby reducing the harmful residual crosslinking agent while maintaining the crosslinked gel structure and its physical properties
2Object-affected harmful factors
If the ratio of crosslinking agent is lowered to reduce side effects, then the probability of side effects is reduced, but the durability and physical properties deteriorate
Solution Approach 1:
The patent changes multiple parameters simultaneously: uses low crosslinking agent ratio (0.01-5 mol%), optimizes crosslinking time and temperature, and adjusts purification conditions to maintain gel integrity while reducing crosslinking agent concentration
Solution Approach 2:
The patent creates a composite system combining crosslinked hyaluronic acid gel with controlled pore structure and optimized molecular weight distribution, thereby achieving mechanical strength through structural design rather than relying solely on high crosslinking agent concentration
3Loss of time
If primary crushing is performed to shorten purification time, then the purification time is shortened, but the crosslinked hyaluronic acid gel swells and physical properties are reduced
Solution Approach 1:
The patent performs preliminary crosslinking to form a stable gel structure before purification, and conducts purification at controlled temperature and ionic strength conditions that prevent excessive swelling, thereby maintaining physical properties while achieving efficient purification
Solution Approach 2:
The patent changes purification conditions by controlling ionic strength, pH, and temperature during the purification process to minimize gel swelling while maintaining efficient removal of unreacted crosslinking agent and byproducts
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves controlled drug release and enhanced physical properties, providing effective and safe pain management with single administration.
Implementation Method 1
a crosslinked hyaluronic acid gel was formed to the conventional hyaluronic acid
Implementation Method 2
uncrosslinked hyaluronic acid alone is decomposed within a few days in vivo
Data Source
AI summary
The present invention relates to a drug delivery composition using crosslinked hyaluronic acid, a manufacturing method therefor, and a pharmaceutical composition comprising the drug delivery composition and a drug and having a desired release behavior.